The FDA has just approved VEOZAH™ tablets for oral use for the treatment of moderate to severe (VMS) hot flashes and/or night sweats due to menopause. 60% to 80% of women experience these symptoms during or after the menopause transition and can have a disruptive impact on women’s daily activities and overall quality of life. VEOZAH™ is the first nonhormonal approved treatment. Thank you for those who volunteered for MediSphere’s SKYLIGHT clinical study for this long awaited nonhormonal treatment.
Success Stories
MediSphere News and Accolades
